Date:7/30/2009

uccessfully identify, complete and integrate any future acquisitions and the effects of any such acquisitions on PDI's ongoing business; the ability to meet performance goals in incentive-based and revenue sharing arrangements with clients; competition in PDI's industry; the ability to attract and retain qualified sales representatives and other key employees and management personnel; product liability claims against PDI; changes in laws and healthcare regulations applicable to PDI's industry or PDI's, or its clients', failure to comply with such laws and regulations; the ability to increase revenues and successfully manage the size of PDI's operations; volatility of PDI's stock price and fluctuations in its quarterly revenues and earnings; potential liabilities associated with insurance claims; failure of, or significant interruption to, the operation of its information technology and communications systems; the results of any future impairment testing for goodwill and other intangible assets; and the risk factors detailed from time to time in PDI's periodic filings with the Securities and Exchange Commission, including without limitation, PDI's Annual Report on Form 10-K for the year ended December 31, 2008, and PDI's subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, PDI undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

'/>"/>

SOURCE PDI, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development
2. Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer
3. Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board
4. FlowCardia, Inc. Appoints Chris Barys to Chief Operating Officer
5. Exosome Diagnostics Appoints Former Roche Executive Greg Zdechlik as Chief Operating Officer
6. ERT Appoints New Vice President of Project Management
7. NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board
8. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
9. Progenitor Cell Therapy Appoints VP of Manufacturing Operations
10. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
11. Covance Appoints Dr. Steven M. Michael as Vice President and Chief Scientific Officer of Global Bioanalytical Services